My guess would be that Pharma would move out of Rochester. Rochester is the sight of Vision Care. It may be easier to separate Pharma from Vision Care so that a new company can buy just Vision Care or just Pharma rather than having to purchase both.
Obviously, four locations Tampa, New Jersey, Rochester and Cali for a relatively small Pharma organization is silly. Private equity firms are suppose to fix these problems before sale not pass them on to the next company.
The NJ office was opened to accommodate a few overpaid individuals that lived in the area. A lot of money was wasted relocating or rehiring to fill the office, mostly Schering Plough courtesy hires. There was and still is no need to have any Pharma in NJ.
The NJ office was opened to accommodate a few overpaid individuals that lived in the area. A lot of money was wasted relocating or rehiring to fill the office, mostly Schering Plough courtesy hires. There was and still is no need to have any Pharma in NJ.
How wasteful. If B+L is serious about selling this company they should announce the closing of the NJ facility in January. Gross inefficiencies do not go unnoticed during a negotiation.
Obviously, four locations Tampa, New Jersey, Rochester and Cali for a relatively small Pharma organization is silly. Private equity firms are suppose to fix these problems before sale not pass them on to the next company.
NJ= just offices no pharma
Tampa= extremely small pharma...more of troubleshoot manufacturing...i.e. no real R&D
Rochester = real R&D, all top researchers and projects located here
Cali= real R&D professionals here.
NJ= just offices no pharma
Tampa= extremely small pharma...more of troubleshoot manufacturing...i.e. no real R&D
Rochester = real R&D, all top researchers and projects located here
Cali= real R&D professionals here.
